{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:13:52Z","timestamp":1783660432924,"version":"3.55.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-\u03b1) that is widely used for induction and maintenance therapy in pediatric inflammatory bowel disease (IBD), yet its effects on the developing intestinal microbiome and treatment response remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically synthesize evidence on IFX-associated microbiome changes in pediatric IBD and evaluate microbiome features linked to treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted following the PRISMA 2020 guidelines. PubMed, Scopus, Embase, and CENTRAL were searched from database inception until March 2026, and our results were synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 945 records identified, 13 studies met the inclusion criteria, comprising 242 pediatric patients. Findings for alpha diversity were variable across studies. In contrast, beta-diversity patterns, taxonomic profiles, and functional analyses more consistently showed positive IFX-associated microbial changes. Responders to treatment more frequently showed enrichment of beneficial taxa, including\n                      <jats:italic>Faecalibacterium, Subdoligranulum,<\/jats:italic>\n                      and\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      , while non-responders exhibited a tendency towards dysbiotic microbial signatures, evidenced by increased levels of\n                      <jats:italic>Gammaproteobacteria<\/jats:italic>\n                      and\n                      <jats:italic>Candida<\/jats:italic>\n                      . Functional and metabolomic studies suggested beneficial shifts in bile-acid metabolism, short-chain fatty acid-related pathways, and inflammatory signaling post IFX treatment. Clinical and biochemical improvements with IFX were consistently reported; however, these improvements were not always accompanied by uniform recovery of overall microbial diversity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In pediatric IBD, IFX is more consistently associated with shifts in microbial composition and function than with broad increases in overall microbial diversity. Further large, standardized studies are warranted to refine the role of microbiome features in biologic treatment stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251133625<\/jats:ext-link>\n                      , identifier CRD420251133625.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1877033","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:25:46Z","timestamp":1783657546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Hala","family":"Altaher","sequence":"first","affiliation":[{"name":"College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Al-Mashhadani","sequence":"additional","affiliation":[{"name":"College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameen","family":"Usman","sequence":"additional","affiliation":[{"name":"College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Ghelani","sequence":"additional","affiliation":[{"name":"College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem K.","family":"Jan","sequence":"additional","affiliation":[{"name":"College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20102529","article-title":"A review on the use of Anti-TNF in children and adolescents with inflammatory bowel disease","volume":"20","author":"Aardoom","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/ibd\/izac194","article-title":"Searching for a consensus among inflammatory bowel disease studies: a systematic meta-analysis","volume":"29","author":"Abdel-Rahman","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph17207618","article-title":"The gut microbiota and inflammation: an overview","volume":"17","author":"Al","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/archdischild-2023-325668","article-title":"Inflammatory bowel disease: recent developments","volume":"109","author":"Ashton","year":"2024","journal-title":"Arch. Dis. Child."},{"key":"B5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/ismej.2017.119","article-title":"Exact sequence variants should replace operational taxonomic units in marker-gene data analysis","volume":"11","author":"Callahan","year":"2017","journal-title":"ISME J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0311604","DOI":"10.1371\/journal.pone.0311604","article-title":"Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients","volume":"19","author":"Carlsen","year":"2024","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1174832","DOI":"10.3389\/fmicb.2023.1174832","article-title":"Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis","volume":"14","author":"Dahal","year":"2023","journal-title":"Front. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/ecco-jcc\/jjaa039","article-title":"Metabonomics and the gut microbiome associated with primary response to Anti-TNF therapy in Crohn's Disease","volume":"14","author":"Ding","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1084\/jem.20180448","article-title":"The gut microbiome: relationships with disease and opportunities for therapy","volume":"216","author":"Durack","year":"2019","journal-title":"J. Exp. Med."},{"key":"B13","volume-title":"Infliximab. Statpearls","author":"Fatima","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00248-021-01697-9","article-title":"Paediatric inflammatory bowel disease and its relationship with the microbiome","volume":"82","author":"Fitzgerald","year":"2021","journal-title":"Microb. Ecol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.07.005","article-title":"Using the full PICO model as a search tool for systematic reviews resulted in lower recall for some PICO elements","volume":"127","author":"Frandsen","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOP.0000000000000576","article-title":"The importance of the microbiome in pediatrics and pediatric infectious diseases","volume":"30","author":"Gaufin","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/immuno4040026","article-title":"Gut microbiome as a target of intervention in inflammatory bowel disease pathogenesis and therapy","volume":"4","author":"Hetta","year":"2024","journal-title":"Immuno"},{"key":"B19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/ibd\/izac182","article-title":"Quantitative fecal microbiota profiles relate to therapy response during induction with tumor necrosis factor \u03b1 antagonist infliximab in pediatric inflammatory bowel disease","volume":"29","author":"H\u00f6yhty\u00e4","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ecco-jcc\/jjad126","article-title":"Faecal bacteriome and metabolome profiles associated with decreased mucosal inflammatory activity upon Anti-TNF therapy in paediatric crohn's disease","volume":"18","author":"Hurych","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41579-025-01163-0","article-title":"Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities","volume":"23","author":"Iliev","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3389\/fmicb.2016.00459","article-title":"Characterization of the gut microbiome using 16S or shotgun metagenomics","volume":"7","author":"Jovel","year":"2016","journal-title":"Front. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ajg.2015.149","article-title":"Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation","volume":"110","author":"Kolho","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/MPG.0000000000003046","article-title":"The use of fecal calprotectin testing in paediatric disorders: a position paper of the european society for paediatric gastroenterology and nutrition gastroenterology committee","volume":"72","author":"Koninckx","year":"2021","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21307\/pjm-2019-014","article-title":"Dependence of colonization of the large intestine by candida on the treatment of crohn's disease","volume":"68","author":"Kowalska-Duplaga","year":"2019","journal-title":"Pol. J. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/jcm9030687","article-title":"Changes in the intestinal microbiota are seen following treatment with infliximab in children with Crohn\u2019s disease","volume":"9","author":"Kowalska-Duplaga","year":"2020","journal-title":"J. Clin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1097779","DOI":"10.3389\/fped.2023.1097779","article-title":"Infantile-onset inflammatory bowel disease has variable long-term outcomes","volume":"11","author":"Krauthammer","year":"2023","journal-title":"Front. Pediatr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"879170","DOI":"10.3389\/fphar.2022.879170","article-title":"Gut microbiota metabolism of azathioprine: a new hallmark for personalized drug-targeted therapy of chronic inflammatory bowel disease","volume":"13","author":"Lazarevic","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0078324","DOI":"10.1128\/msystems.00783-24","article-title":"Profiles and interactions of gut microbiome and intestinal microRNAs in pediatric Crohn's disease","volume":"9","author":"Lv","year":"2024","journal-title":"mSystems"},{"key":"B32","doi-asserted-by":"publisher","first-page":"114985","DOI":"10.1016\/j.biopha.2023.114985","article-title":"Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: a review","volume":"164","author":"Ma","year":"2023","journal-title":"Biomed. and Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"9002193","DOI":"10.1155\/agm3\/9002193","article-title":"Gut microbiome variability in pediatric patients with inflammatory bowel disease","volume":"2025","author":"Maeder","year":"2025","journal-title":"Adv. Gut and Microbiome Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/pathogens12020262","article-title":"Assessing the relationship between the gut microbiota and inflammatory bowel disease therapeutics: a systematic review","volume":"12","author":"Mah","year":"2023","journal-title":"Pathogens"},{"key":"B35","doi-asserted-by":"publisher","first-page":"897936","DOI":"10.3389\/fmed.2022.897936","article-title":"Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Marsal","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ecco-jcc\/jjv147","article-title":"Altered fecal microbiota in paediatric inflammatory bowel disease","volume":"9","author":"Maukonen","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"B37","volume-title":"Inflammatory Bowel Disease. Statpearls","author":"McDowell","year":"2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"B39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5223\/pghn.2019.22.1.50","article-title":"Clinical aspects and treatments for pediatric inflammatory bowel diseases","volume":"22","author":"Moon","year":"2019","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.20517\/mrr.2023.41","article-title":"Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches","volume":"2","author":"O'Reilly","year":"2023","journal-title":"Microbiome Res. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10620-018-4917-7","article-title":"Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease","volume":"63","author":"Papamichael","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2040622319838443","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B44","first-page":"57","article-title":"Infliximab therapy in pediatric Crohn's disease: a review","volume":"3","author":"Parashette","year":"2010","journal-title":"Clin. Exp. Gastroenterol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/cmi.12308","article-title":"Defining dysbiosis and its influence on host immunity and disease","volume":"16","author":"Petersen","year":"2014","journal-title":"Cell Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17562848211059954","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Ther. Adv. Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"733992","DOI":"10.3389\/fcimb.2022.733992","article-title":"The gut microbiota in inflammatory bowel disease","volume":"12","author":"Qiu","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/apt.16656","article-title":"Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease","volume":"55","author":"Radhakrishnan","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"26050","DOI":"10.3402\/mehd.v26.26050","article-title":"The composition of the gut microbiota throughout life, with an emphasis on early life","volume":"26","author":"Rodriguez","year":"2015","journal-title":"Microb. Ecol. Health Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/gutjnl-2014-307008","article-title":"Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee","volume":"64","author":"Ruemmele","year":"2015","journal-title":"Gut"},{"key":"B51","doi-asserted-by":"publisher","first-page":"19186","DOI":"10.1038\/s41598-020-76175-2","article-title":"Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis","volume":"10","author":"Sakurai","year":"2020","journal-title":"Sci. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.advms.2020.06.003","article-title":"Quantitative changes in selected bacteria in the stool during the treatment of Crohn's disease","volume":"65","author":"Salamon","year":"2020","journal-title":"Adv. Med. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1038\/s41598-021-88823-2","article-title":"Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment","volume":"11","author":"Sanchis-Artero","year":"2021","journal-title":"Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms23073464","article-title":"Dysbiosis in inflammatory bowel disease: pathogenic role and potential therapeutic targets","volume":"23","author":"Santana","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms8060874","article-title":"Changes in the intestinal microbiota of patients with inflammatory bowel disease with clinical remission during an 8-Week infliximab infusion cycle","volume":"8","author":"Seong","year":"2020","journal-title":"Microorganisms"},{"key":"B56","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ Br. Med. J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-042320-021020","article-title":"The gut microbiome and inflammatory bowel diseases","volume":"73","author":"Shan","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3390\/ijms26062503","article-title":"Gut Microbiota serves as a crucial independent biomarker in Inflammatory bowel disease (IBD)","volume":"26","author":"Sharma","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cgh.2018.08.054","article-title":"The gut microbiome in adult and pediatric functional gastrointestinal disorders","volume":"17","author":"Shin","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/MPG.0000000000003589","article-title":"Outcomes and predictors of sustained remission after drug withdrawal in pediatric crohn disease","volume":"75","author":"Stein","year":"2022","journal-title":"J. Pediatr. Gastroenterology Nutr."},{"key":"B61","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/apt.16086","article-title":"Multiomic features associated with mucosal healing and inflammation in paediatric Crohn\u2019s disease","volume":"52","author":"Taylor","year":"2020","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/nu14020260","article-title":"Intestinal taxa abundance and diversity in inflammatory bowel disease patients: an analysis including covariates and confounders","volume":"14","author":"Teofani","year":"2022","journal-title":"Nutrients"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1042\/BCJ20160510","article-title":"Introduction to the human gut microbiota","volume":"474","author":"Thursby","year":"2017","journal-title":"Biochem. J."},{"key":"B65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/B978-0-323-90960-0.00009-6","article-title":"Chapter 3 - inflammation: a multifaceted and omnipresent phenomenon","volume-title":"Inflammation and Obesity","author":"Tyszkowski","year":"2023"},{"key":"B66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jgh.16043","article-title":"Microbiome and metabolome in inflammatory bowel disease","volume":"38","author":"Upadhyay","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0189424","DOI":"10.1128\/spectrum.01894-24","article-title":"The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab","volume":"13","author":"Ventin-Holmberg","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B68","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1038\/s41598-022-10548-7","article-title":"The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-\u03b1","volume":"12","author":"Ventin-Holmberg","year":"2022","journal-title":"Sci. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aap8914","article-title":"Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Vich Vila","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e70047","DOI":"10.1049\/syb2.70047","article-title":"Gut microbiome and paediatric inflammatory bowel disease: emerging mechanistic and therapeutic insights into pathogenesis and microbiota-based approaches","volume":"19","author":"Wang","year":"2025","journal-title":"IET Syst. Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ecco-jcc\/jjx153","article-title":"Characteristics of faecal microbiota in paediatric Crohn's Disease and their dynamic changes during infliximab therapy","volume":"12","author":"Wang","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1865708","article-title":"Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Microbes"},{"key":"B73","volume-title":"Covidence Systematic Review Software","year":"2020"},{"key":"B74","doi-asserted-by":"publisher","first-page":"652725","DOI":"10.3389\/fmicb.2021.652725","article-title":"The interactions between Candida albicans and mucosal immunity","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Microbiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/ibd\/izaa253","article-title":"Fecal microbiota alterations associated with clinical and endoscopic response to Infliximab therapy in Crohn's Disease","volume":"26","author":"Zhuang","year":"2020","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:25:48Z","timestamp":1783657548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":75,"alternative-id":["10.3389\/fphar.2026.1877033"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1877033","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1877033"}}